Demonstrating strong customer focus and therapeutic expertise, TFS CRO has been awarded new Covid-19 studies.

TFS is working in collaboration with sponsors, at an unprecedented pace. Our operational teams are participating in various studies, targeting coronavirus disease patients or analyzing the real world evidence to bring treatments to COVID-19 patients faster. TFS is continuously recognized for agility as well as the knowledge and experience of our teams.

In-depth expertise in the field of internal medicine as well as strong presence in Spain allow TFS to partner with customers on four more trials on Covid-19. The studies total up to more than 3300 patients in 17 sites covering full a spectrum of COVID-19 patient population from ICU patients, hospitalized pneumonia and non-severe confirmed cases.

Speaking about TFS’s involvement in these studies, Dr. Bassem Saleh, CEO said "We are hopeful that we can play a significant role in the global effort to find suitable treatment options for COVID-19 patients. TFS is well- positioned to manage studies requiring extensive local knowledge and an established network. We have exceptional relationships with sites and KOLs globally, and we have processes in place to effectively manage COVID-19 trials.”

About TFS TFS was founded in 1996 and has grown to become the leading global mid-size clinical CRO focusing on small and mid-size
Biotech customers. TFS employs nearly 700 professionals throughout 21 countries and currently delivers clinical research
services in more than 40 countries. We provide end-to-end solutions including full clinical development services, strategic
resourcing and flexible single services. Our partnering approach with customers is based on our four business principles –
commitment, flexibility, value creation and global reach. Our core therapeutic specialties are Dermatology, Hematology and
Oncology, Ophthalmology as well as Internal Medicine and Neurology
Detailed information about TFS, and its business offerings can be obtained through www.tfscro.com

For further information, please contact:

Sylwia Domagalska

Director Corporate Communications

Email: sylwia.domagalska@tfscro.com

Phone: +48 787 913 074

Tags: